Abstract S100A8/A9, also known as “calprotectin” or “MRP8/14,” is an alarmin primarily
secreted by activated myeloid cells with antimicrobial, proinflammatory, and prothrombotic …

The prevalence of gestational diabetes mellitus (GDM) has increased in recent years, along
with the higher prevalence of obesity in women of reproductive age. GDM is a pathology …

GPVI is a critical signaling receptor responsible for collagen-induced platelet activation and
a promising anti-thrombotic target in conditions such as coronary artery thrombosis …

Purpose We aimed to investigate potential synergistic antiplatelet effects of Ginkgo biloba
extract (GBE50) in combination with aspirin using in vitro models. Methods Arachidonic acid …

Background Adenosine inhibits the activation of most immune cells and platelets. Selective
adenosine A2A receptor (A2AR) agonists such as regadenoson (RA) reduce inflammation in …

Collagen has been proposed to bind to a unique epitope in dimeric glycoprotein VI (GPVI)
and the number of GPVI dimers has been reported to increase upon platelet activation …

The platelet aggregation inhibitory activity of selected xanthine-based adenosine A2A and
A2B receptor antagonists was investigated, and attempts were made to explain the …

CLEC-2 is a target for a new class of antiplatelet agent. Clustering of CLEC-2 leads to
phosphorylation of a cytosolic YxxL and binding of the tandem SH2 domains in Syk …

Background To assess differences in platelet inhibition during ticagrelor monotherapy (TIC)
or dual therapy with ticagrelor and aspirin (TIC+ ASP) in patients after percutaneous …

Abstract Background The glycoprotein (GP) Ib-IX-V complex is a unique platelet plasma
membrane receptor, which is essential for platelet adhesion and thrombus formation. GPIbα …